Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Sleep and Seizures: Emerging Insights From AAN 2025," Nancy Foldvary-Schaefer, DO, director of the Sleep Disorders Center at Cleveland Clinic, reflected on key sleep-related topics presented at this year’s AAN Annual Meeting. She highlighted the growing clinical interest in underrecognized conditions like idiopathic hypersomnia and narcolepsy, stressing the need for better awareness and earlier diagnosis. Foldvary-Schaefer also detailed the development of the Sleep by Cleveland Clinic mobile app, designed to improve screening for common sleep disorders with validated tools and real-time resources. Additionally, she discussed new findings on the prevalence of obstructive sleep apnea in adults with epilepsy, pointing to the importance of routine sleep screening in this population, regardless of seizure severity. Finally, she shared exploratory data on SSRI use and peri-ictal respiratory patterns in epilepsy, offering new perspectives on potential protective mechanisms tied to SUDEP risk.
Looking for more neuromuscular discussion? Check out the NeurologyLive® Sleep disorders clinical focus page.
Episode Breakdown:
1:00 – Key sleep topics discussed at AAN 2025 and the growing interest in hypersomnia
5:45 – Development and purpose of the SLEEP mobile app by Cleveland Clinic
10:35 – Findings on obstructive sleep apnea prevalence in adults with epilepsy
15:05 – Neurology News Minute
17:10 – The need for sleep disorder screening in epilepsy clinical trials
19:45 – Exploratory findings on SSRI use and respiratory patterns in patients with epilepsy
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Approves Pre-Filled Syringe Administration for FcRn Modulator EfgartigimodFDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic MigraineFDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.